CD146/可溶性CD146通路是增生性糖尿病视网膜病变血管生成与炎症的新型生物标志物
该研究检测了41例增生性糖尿病视网膜病变(PDR)患者和27例非糖尿病患者的玻璃体样本,以及18例PDR患者的视网膜前纤维血管膜,发现PDR患者玻璃体中sCD146和VEGF水平显著升高。机制上sCD146可诱导Müller细胞和视网膜微血管内皮细胞的多条炎症与血管生成信号通路活化,并在正常大鼠中增加视网膜血管通透性,提示CD146/sCD146通路参与PDR的发生发展。
要点
- PDR患者玻璃体中sCD146和VEGF水平显著高于非糖尿病患者。
- 视网膜前膜中CD146表达于白细胞、血管内皮细胞和肌成纤维细胞。
- sCD146玻璃体内注射可增加正常大鼠视网膜血管通透性。
核心结论
- CD146/sCD146通路参与增生性糖尿病视网膜病变的起始和进展。
研究设计与样本
- 研究纳入41例PDR患者和27例非糖尿病患者的玻璃体样本,以及18例PDR患者的视网膜前纤维血管膜。
- 采用ELISA、Western blot、免疫组化和免疫荧光显微镜分析,并检测大鼠视网膜、人视网膜微血管内皮细胞和Müller胶质细胞。
- 用异硫氰酸荧光素标记的葡聚糖评估血视网膜屏障破坏。
主要发现
- PDR患者玻璃体中sCD146和VEGF水平显著高于非糖尿病患者。
- 视网膜前膜免疫组化显示CD146表达于白细胞、血管内皮细胞和肌成纤维细胞。
- 表达CD31的血管数量与表达CD146的血管及基质细胞数量呈显著正相关。
- 糖尿病大鼠视网膜中CD146在Western blot分析中显著增加。
- sCD146诱导Müller细胞中磷酸化ERK1/2、NF-κB、VEGF和MMP-9上调。
关键数值与推荐
- 氯化钴、VEGF和TNF-α诱导人视网膜微血管内皮细胞中sCD146上调。
- MMP抑制剂ONO-4817减弱TNF-α诱导的人视网膜微血管内皮细胞sCD146上调。
- 正常大鼠玻璃体内注射sCD146显著增加视网膜血管通透性,并上调视网膜中磷酸化ERK1/2、ICAM-1和VEGF。
- sCD146诱导人视网膜微血管内皮细胞迁移。
临床怎么用
- sCD146可能作为PDR血管生成和炎症活动的生物标志物。
- CD146/sCD146通路可能成为PDR治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inflammation, angiogenesis and fibrosis are pathological hallmarks of proliferative diabetic retinopathy (PDR). The CD146/sCD146 pathway displays proinflammatory and proangiogenic properties. We investigated the role of this pathway in the pathophysiology of PDR. METHODS: Vitreous samples from 41 PDR and 27 nondiabetic patients, epiretinal fibrovascular membranes from 18 PDR patients, rat retinas, human retinal microvascular endothelial cells (HRMECs) and human retinal Müller glial cells were studied by ELISA, Western blot analysis, immunohistochemistry and immunofluorescence microscopy analysis. Blood-retinal barrier breakdown was assessed with fluorescein isothiocyanate-conjugated dextran. RESULTS: sCD146 and VEGF levels were significantly higher in vitreous samples from PDR patients than in nondiabetic patients. In epiretinal membranes, immunohistochemical analysis revealed CD146 expression in leukocytes, vascular endothelial cells and myofibroblasts. Significant positive correlations were detected between numbers of blood vessels expressing CD31, reflecting angiogenic activity of PDR, and numbers of blood vessels and stromal cells expressing CD146. Western blot analysis showed significant increase of CD146 in diabetic rat retinas. sCD146 induced upregulation of phospho-ERK1/2, NF-κB , VEGF and MMP-9 in Müller cells. The hypoxia mimetic agent cobalt chloride, VEGF and TNF-α induced upregulation of sCD146 in HRMECs. The MMP inhibitor ONO-4817 attenuated TNF-α-induced upregulation of sCD146 in HRMECs. Intravitreal administration of sCD146 in normal rats significantly increased retinal vascular permeability and induced significant upregulation of phospho-ERK1/2, intercellular adhesion molecule-1 and VEGF in the retina. sCD146 induced migration of HRMECs. CONCLUSIONS: These results suggest that the CD146/sCD146 pathway is involved in the initiation and progression of PDR.
引用
- Abu El-Asrar AM, Nawaz MI, Ahmad A, et al. CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2021. PMID: 34293080. doi:10.1167/iovs.62.9.32
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。